Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurogene Inc. - Common Stock (NQ: NGNE ) 41.27 -3.56 (-7.95%) Streaming Delayed Price Updated: 3:57 PM EDT, Jul 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 136,841 Open 44.96 Bid (Size) 41.13 (4) Ask (Size) 41.38 (1) Prev. Close 44.83 Today's Range 39.83 - 47.00 52wk Range 12.49 - 53.00 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Neurogene to Participate in BMO Genetic Medicines Summit July 02, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces Addition to Russell 3000® Index July 01, 2024 From Neurogene Inc. Via Business Wire Performance YTD +107.67% +107.67% 1 Month +13.24% +13.24% 3 Month +23.55% +23.55% 6 Month +28.95% +28.95% 1 Year +173.28% +173.28% More News Read More 12 Health Care Stocks Moving In Thursday's Pre-Market Session June 20, 2024 Via Benzinga Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session June 18, 2024 Via Benzinga MicroMarvel Neurogene Challenges Big Pharma January 22, 2024 Via Talk Markets Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome June 18, 2024 From Neurogene Inc. Via Business Wire Neurogene to Participate in Upcoming Conferences June 05, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program June 03, 2024 From Neurogene Inc. Via Business Wire NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 May 10, 2024 Via InvestorPlace Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates May 10, 2024 From Neurogene Inc. Via Business Wire Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting May 07, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting April 22, 2024 From Neurogene Inc. Via Business Wire 7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 April 12, 2024 Via InvestorPlace Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates March 18, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial March 04, 2024 From Neurogene Inc. Via Business Wire Neurogene to Participate in Upcoming Investor Conferences February 29, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer January 16, 2024 From Neurogene Inc. Via Business Wire Neurogene Announces Business Update and 2024 Outlook January 05, 2024 From Neurogene Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
